제일파마홀딩스

002620KOSPI회사 본부 및 경영 컨설팅 서비스업

53.5 / 100

Reference Date: 2026-04-13

Financial Score24.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Revenue is on a declining trend. Declined 12.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Jeil Pharma Holdings was formed through a corporate split in 2017, operating as a holding company overseeing investments, while its subsidiary Jeil Pharmaceuticals focuses on pharmaceutical manufacturing and sales. Key subsidiaries include Jeil Health Sciences (general pharmaceuticals) and Jeil & Partners (sales agency), with major products such as Lipito, Lyrica, and Kepentec. The company's core businesses include management consulting, leasing, investment income, and pharmaceutical sales.

Number of Employees

40people

Average Salary

73.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

3.76Industry Average 5.246.5Point

Lower than industry avg (good)

PBR

0.28Industry Average 0.364.0Point

In line with industry avg

ROE

7.64Industry Average 4.785.5Point

1.6x industry avg (good)

Debt Ratio

18.01Industry Average 29.295.0Point

Lower than industry avg (good)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲139.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -3.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (35%)

Current 8,150Won52-week high 9,28052-week low 7,530

1-month return1.0Point

1m -12.18% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral정기주주총회결과2026-03-24
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-24
Neutral[첨부정정]사업보고서 (2025.12)2026-03-16
Neutral사업보고서 (2025.12)2026-03-16
Neutral감사보고서제출2026-03-16